【ChiCTR2600132897】Effectiveness of a Structured Diet and Exercise Plan on Sticking With It and Managing Cardiometabolic Health During and After Pregnancy
ChiCTR2600132897
结束
/
/
/
2026-09-20
/
/
Overweight and Obesity
Effectiveness of a Structured Diet and Exercise Plan on Sticking With It and Managing Cardiometabolic Health During and After Pregnancy
Effectiveness of a Structured Diet and Exercise Plan on Sticking With It and Managing Cardiometabolic Health During and After Pregnancy
i. To assess the status of dietary intake, physical activity, and related weight, blood pressure, heart rate, glucose tolerance, circulating free fatty acids, and total, LDL and HDL cholesterol changes occurring during pregnancy among women with a sedentary lifestyle and/or overweight/obesity. ii. To investigate whether the provision of a structured physical activity prescription improves compliance with physical activity recommendations among women with a sedentary lifestyle and/or overweight/obesity. iii. To investigate whether the provision of a structured diet prescription improves compliance with dietary recommendations among women with a sedentary lifestyle and/or overweight/obesity. iv. To determine the effectiveness of a structured physical activity prescription in controlling weight, blood pressure, heart rate, Hb concentration, glucose tolerance, circulating free fatty acids, total, LDL and HDL cholesterol during pregnancy and their subsequent return to prepregnancy levels among women with a sedentary lifestyle and/or overweight/obesity. v. To determine the effectiveness of a structured diet prescription in controlling weight, blood pressure, heart rate, Hb concentration, glucose tolerance, circulating free fatty acids, total, LDL and HDL cholesterol during pregnancy and their subsequent return to pre-pregnancy levels among women with a sedentary lifestyle and/or overweight/obesity. vi. To assess the effects of structured diet and exercise prescriptions on pregnancy outcomes among women with a sedentary lifestyle and/or overweight/obesity.
非随机对照试验
其它
No randomization. It will be squencial sampling. All eligible at Makole health center will be assigned to experiment group while all eligible at Makole Dispensary will be asigned to comparison group.
None
UDOM sponsorship for staff undertaking PhD studies
/
107
/
2025-04-01
2026-04-30
/
The study will include singleton pregnant women aged 18–35 with a sedentary lifestyle and/or overweight or obese. The study will recruit only pregnant women at 6–16 weeks of gestation. The study will only include women able to give valid informed consent and willing to participate and follow the prescription. The study will include singleton pregnant women aged 18–35 with a sedentary lifestyle and/oroverweight or obese. The study will recruit only pregnant women at 6–16 weeks of gestation. The study will only include women able to give valid informed consent and willing to participateand follow the prescription.;
请登录查看Gestation below six weeks will not be included due to the difficulty of diagnosing pregnancy. Also, if gestational age was not ascertained by ultrasound examination by the end of 13 weeks of their gestation will be excluded. Potential participants with multiple pregnancies will not be included to rule out the probable multiplicity of pregnancy changes. Under–18 women will not be included to exclude the possible effects of premature reproductive systems, while those above 35 will not be included to exclude the possible effects of pregnancy at an advanced age. Women already diagnosed with cardiovascular disease or for whom exercise is contraindicated will be excluded. All potential participants will be screened for contraindications using Canadian guidelines before enrolment. To minimise the loss of follow-ups, potential participants planning to relocate out of Dodoma City during the study period will be excluded.;
请登录查看University of Dodoma
/
University of Dodoma的其他临床试验
University of Dodoma的其他临床试验
最新临床资讯
-
飞眸医疗首例人体临床试验(FIH)成功开展,国产飞秒屈光设备竞逐540亿屈光市场
动脉网-最新2026-09-10
-
和铂医药:超长效靶向TSLP抗体哮喘二期临床取得阳性结果,三期临床已启动
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
医药笔记2026-09-09
-
动脉网-最新2026-09-09
-
药明康德2026-09-09
-
一度医药2026-09-08
-
阿斯利康中国2026-09-08
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-09-26
-
2026-09-26
-
2026-09-26
-
摩熵咨询 20 8
-
摩熵咨询 20 11
-
摩熵咨询 34 56
-
颁布机构:国家药品监督管理局 2026-09-10
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构:国家医保局 2026-07-31
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-09-26
-
2026-09-26
-
2026-09-26
-
摩熵咨询 35 71
-
摩熵咨询 28 60
-
摩熵咨询 34 42
-
颁布机构:国家市场监督管理总局 2026-09-18
-
颁布机构:国家市场监督管理总局 2026-09-17
-
颁布机构:国家市场监督管理总局 2026-08-10
